Clinical trial manufacturing / CTM
Clinical trials are a cornerstone of modern drug development. They follow preclinical research and involve testing new therapeutic candidates in humans to assess safety, efficacy and tolerability. During late-stage studies, large-scale clinical data determine optimal dosage, administration routes and comparative performance against existing treatments, supporting regulatory approval and market introduction. Beyond their regulatory function, clinical trials drive medical progress, offering patients early access to innovative therapies and contributing to advances in healthcare outcomes.
While the objectives of clinical and commercial manufacturing are related, their execution differs substantially. Clinical trial manufacturing (CTM) is a specialised form of pharmaceutical production focused on supplying drugs for use in controlled clinical research. Unlike large-scale commercial manufacture, CTM requires exceptional flexibility, precision and documentation, as each batch must align with specific study protocols and stringent regulatory standards.
CTM of parenteral drugs, including intravenous, subcutaneous and intramuscular formulations, is particularly demanding, as it involves producing precisely controlled batches that must meet specific aseptic, packaging and labelling requirements. CTM projects inherently involve numerous variables and must be synchronised with timelines of the clinical study conducted. Any delay or deviation in the manufacture or supply of clinical trial materials can compromise the success of a trial.
The acronym CTM is also commonly used to denote Clinical Trial Materials. These include both active pharmaceutical ingredients and finished drug products intended for clinical use. As development progresses, the formulation and supply of sterile injectables and parenteral dosage forms often become critical to the continuity of clinical programmes.
Before CTM production begins, a detailed manufacturing plan and timeline are established, typically prior to the submission of the Investigational Medicinal Product Dossier and activation of clinical sites. Experienced Contract Development and Manufacturing Organisations play a vital role in this stage, offering technical insight, regulatory expertise and agile process management.
MediPharm’s Capabilities
MediPharm offers an integrated suite of CTM services supporting early- and late-phase clinical programmes, covering drug substance intermediates and finished dosage forms. Our GMP-compliant facilities are optimised for lyophilised products, sterile injectables and phase-appropriate GMP production, complemented by:
In-house analytical and microbiological quality control
Primary and secondary packaging, labelling and kitting
Non-GMP feasibility studies for accelerated process development
Through integrated analytical development, real-time process monitoring and lyophilisation expertise, MediPharm can help to achieve a seamless transition from laboratory to clinical-grade production. Our platform enables flexible, cost-efficient and high-quality manufacturing, fully aligned with EU GMP standards and tailored to the needs of pharmaceutical innovators advancing towards clinical validation.